The Alkaptonuria Drug Market is characterized by its "ultra-orphan" status, targeting a patient population estimated at 1 in 250,000 to 1,000,000 people worldwide. The primary goal of current pharmacotherapy is to inhibit the HGD cascade to reduce HGA levels, thereby slowing the progression of irreversible tissue damage. https://logcla.com/blogs/947640/Low-Zero-Sugar-Energy-Drinks-Segment-Dominance-and-Revenue-Projection